Rhinovirus Infection Therapeutics Pipeline Analysis

Rhinovirus is a small, non-enveloped, icosahedral virus having size of around 27 nm diameter. It contains one positive-strand RNA and belongs to Picornavirus family. Discovered in 1956, rhinovirus has over 100 antigenically distinct serotypes such as RhV A, RhV B groups, and RhV A2 and RhV C subclasses, based on their sequence similarity and cell entry receptors. Human rhinovirus is a positive-sense RNA virus of 7.2 kb single strand, having single open reading frame joined to a 5′ untranslated region and a short viral priming protein. HRV A, HRV B and HRV C, are subtypes of human rhinovirus species, responsible for human diseases such as respiratory tract infection. Approximately 200 different viruses 30%-50% of all cases are known to cause symptoms of the common cold. The symptoms of the rhinovirus infection depend on the pathology associated with it. The most common symptoms include runny nose, nasal congestion, fever, headache, cough, sneezing, sore throat, rhinorrhea, croup in infants, tracheitis, and malaise that may last for 1 – 2 weeks.

Explore Report at: https://www.psmarketresearch.com/market-analysis/rhinovirus-infection-therapeutics-pipeline-analysis

The rhinovirus infection therapeutics pipeline has more than 15 drugs. In pipeline analysis, drugs are analyzed on the basis of route of administration and molecule type. The pipeline is also analyzed on the basis of monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Preclinical stage.

Browse Report Sample at: https://www.psmarketresearch.com/market-analysis/rhinovirus-infection-therapeutics-pipeline-analysis/report-sample

Clinical development pipeline analysis provides description about the key companies developing rhinovirus infection drugs. Some of the key players actively involved in the research and development are Novartis AG, Bioorganic Research and Services, S.A., Atopix Therapeutics, Ltd., Meissa Vaccines, Inc., 3-V Biosciences, Inc., Astrazeneca plc and AIMM Therapeutics.

Designed by CyFocus.com
Powered by CyFocus.net
%d bloggers like this: